Clinical Trials Logo

Clinical Trial Summary

This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.


Clinical Trial Description

The first part of this study is to identify the maximum tolerated dose (MTD) of allogeneic SARS-CoV2-specific T cells (SARS-CoVSTs) for patients with COVID19 with high risk of progression to mechanical ventilation. The 3 dose levels (DL) are: DL1: 1x10^7 cells (flat dose) DL2: 2x10^7 cells (flat dose) DL3: 4x10^7 cells (flat dose) Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level. After the dose finding phase is complete and the MTD established, a randomized trial will be conducted. Patient will be randomized 1:1 using the permuted block method with a block size of 4 (2 in the treatment arm and 2 in the control arm) to receive treatment with SARS-CoVSTs or routine treatment per institutional standards. All enrolled patients will undergo the following evaluations: - Physical exam and history including height and weight - SARS-CoV-2 test - Blood tests - Chest X-ray or chest CT Scan if not already done in the past 48 hours. - A urine pregnancy test, when applicable Patients randomized to receive SARS-CoVSTs will be pre-medicated with Benadryl and Tylenol. The cells will be thawed and given through an intravenous line. Patients will be monitored for infusion side effects for up to 14 days or until infusion side effects have completely resolved, whichever is longer. Blood will be drawn before the infusion and then up to daily for 14 days or until the patient is discharged from the hospital. Optional blood samples will be drawn at 2, 3 and 6 months after infusion. Study participation will last 6 months after the date of infusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04401410
Study type Interventional
Source Baylor College of Medicine
Contact
Status Terminated
Phase Phase 1
Start date November 4, 2020
Completion date October 12, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Terminated NCT04435457 - Cardiovascular Implications of COVID-19
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A
Completed NCT04369794 - COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Phase 4
Completed NCT04542850 - Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 N/A
Completed NCT04382040 - A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 Phase 2
Completed NCT04378582 - Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT04383587 - Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers N/A
Recruiting NCT04402814 - IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.
Completed NCT04395924 - Maternal-foetal Transmission of SARS-Cov-2
Completed NCT04425889 - COVID-19 Antibodies Among Healthcare Workers
Completed NCT04374565 - Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Phase 2
Not yet recruiting NCT04405492 - Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19 N/A
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers